Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up Following Better-Than-Expected Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $4.45, but opened at $4.55. Taysha Gene Therapies shares last traded at $4.5150, with a volume of 715,255 shares traded.

The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. The company had revenue of $5.49 million during the quarter, compared to analysts’ expectations of $1.89 million. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 62.55%.

Key Taysha Gene Therapies News

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Q4 2025 results topped expectations — reported EPS of ~$-0.087 vs. consensus ~$-0.096 and revenue of $5.49M well above estimates; management highlighted momentum on programs and financial results. Earnings Call Transcript (InsiderMonkey)
• Positive Sentiment: TSHA‑102 pivotal trial enrollment advancing and company says it’s on track to complete dosing in Q2 2026 with a 2026 BLA submission path — a clear clinical catalyst for future value. BLA Submission Path (MSN)
• Positive Sentiment: Analyst optimism picked up — Needham raised its price target to $12 (buy) and Chardan reaffirmed a $12 buy target, signaling sizable upside from current levels and likely contributing to increased attention. Analyst Coverage (Benzinga)
• Positive Sentiment: Company highlighted a strong cash position on the earnings call, which supports ongoing pivotal enrollment and development activity. Earnings Highlights (Yahoo Finance)
• Neutral Sentiment: Full earnings/management commentary and call transcripts are available from multiple outlets for investors who want the full details and Q&A. Transcript (Seeking Alpha)
• Negative Sentiment: Company remains unprofitable with a very negative net margin and negative return on equity; development risk and cash burn remain material risks until regulatory milestones or commercialization are achieved. Full Results & Corporate Update (GlobeNewswire)

Analysts Set New Price Targets

Several research firms have weighed in on TSHA. Wells Fargo & Company increased their target price on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Needham & Company LLC boosted their price objective on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. UBS Group set a $11.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. Finally, Chardan Capital reissued a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.09.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $4.71, for a total transaction of $942,000.00. Following the sale, the insider owned 1,006,439 shares of the company’s stock, valued at $4,740,327.69. This trade represents a 16.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Kamran Alam sold 78,968 shares of the business’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total value of $375,098.00. Following the sale, the chief financial officer owned 1,467,635 shares in the company, valued at $6,971,266.25. This represents a 5.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 598,623 shares of company stock worth $2,822,188 in the last three months. 3.78% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

Several large investors have recently bought and sold shares of the company. Intech Investment Management LLC grew its holdings in shares of Taysha Gene Therapies by 3.6% during the fourth quarter. Intech Investment Management LLC now owns 71,069 shares of the company’s stock worth $391,000 after purchasing an additional 2,443 shares during the last quarter. Chicago Partners Investment Group LLC increased its stake in shares of Taysha Gene Therapies by 1.5% in the fourth quarter. Chicago Partners Investment Group LLC now owns 166,541 shares of the company’s stock valued at $916,000 after buying an additional 2,504 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Taysha Gene Therapies by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company’s stock valued at $73,000 after buying an additional 2,765 shares during the last quarter. Virtus Investment Advisers LLC boosted its position in Taysha Gene Therapies by 7.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 45,946 shares of the company’s stock worth $253,000 after buying an additional 3,008 shares during the period. Finally, Xponance Inc. boosted its position in Taysha Gene Therapies by 29.1% during the 3rd quarter. Xponance Inc. now owns 16,575 shares of the company’s stock worth $54,000 after buying an additional 3,738 shares during the period. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Stock Performance

The company’s 50-day simple moving average is $4.63 and its 200-day simple moving average is $4.55. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -12.94 and a beta of 1.02. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.